Q-omics provides the consensus-scored SNORD105B profile across patient tissues and cancer cell-line models. SNORD105B expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SNORD105B is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, SNORD105B RNA expression shows 6,035 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, STAD, and GBM as cancer lineages where SNORD105B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD105B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD105B survival associations across molecular data types. SNORD105B RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD105B RNA expression–survival associations across cancer types. High SNORD105B expression shows unfavorable associations in SKCM, STAD and UVM, but favorable associations in BLCA, OV and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .015). Together, the overview and detailed table identify BLCA as the clearest survival context for SNORD105B RNA expression.
This table summarizes SNORD105B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD105B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD105B shows higher tumor expression in STAD, COAD and LUAD. The STAD box plot shows higher SNORD105B RNA expression in tumor versus normal tissue (log2 FC = +0.489, t-test p < 0.001).
This table shows molecular features associated with SNORD105B in patient tissues and cancer cell lines. In patient samples, SNORD105B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
